Tools
Hypnic Headache
Introduction
Headaches and chronic pain are amongst the leading cause of morbidity and years lived with disability in the world.[1] Headaches have been classified into various categories based on the International Classification of Headache Disorders criteria.[2] One such headache disorder is a hypnic headache.
Hypnic headache (HH) is a rare headache syndrome that occurs exclusively during sleep, usually at the same time at night. It also has been named before the clockwise headache or alarm clock headache. It is considered a primary headache, according to the international classification of headache disorders.[3]
HH is characterized by attacks of dull headaches that occur after the age of 50 years, at least 15 times per month, and come only during sleep with no associated autonomic symptoms. The attacks wake the patient during sleep and usually last more than 15 minutes after waking.[4]
Hypnic headache is a chronic disorder that can last for years, with no remission of headache.[5]
Patients with migraines and hypertension are more likely to develop HH compared to others. Nearly all patients with HH had some type of motor activity, such as getting out of bed and eating, drinking, showering, or reading when awakened by the headache attack. Still, they did not typically have the restlessness that is seen with cluster headache and trigeminal autonomic cephalalgias.[6]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The exact etiology of HH is unknown. Hypnic headaches might be associated with issues in the parts of the brain involved in pain management, melatonin production, or REM sleep.
Epidemiology
Hypnic headache is thought to be about 0.07% of all patients that come to the office with the chief complaint of headache.
In the geriatric population, the ratio is 1.4%, according to an Italian study.[6]
However, in recent years HH is thought to be slightly more common than in previous studies. It is estimated to be 0.3% to 0.6% in a French study.[7]
Pathophysiology
The timing of hypnic headache and the concomitant diabetes insipidus with a feeling of intense thirst that has been reported by few studies favor the involvement of hypothalamic structures.
It has also been reported that sleep-disordered breathing has not been reported to be of high prevalence in patients diagnosed with HH. Continuous positive airway pressure and nocturnal oxygen supplementation did not improve symptoms in patients with HH.
The onset of HH attacks is associated with rapid eye movement sleep, and this association could connect HH to arterial hypertension and low oxygenation that occur during REM sleep.
The suprachiasmatic nucleus (SCN) remains a possible region involved in the origin of HH. As the body ages, the cell numbers in the suprachiasmatic nucleus decrease significantly, which leads to a decrease in melatonin. The release of melatonin will be affected by the reduced SCN cells. The SCN projects to and receives afferents from brainstem periaqueductal gray, which means a pain modulating link is possible.[8][9]
History and Physical
Patients usually describe the headache as frequent recurrent headaches occurring only during sleep. They cause wakening and last for up to 4 hours. There are no characteristic associated symptoms and not attributed to other pathology. The formal criteria require according to ICHD-3 headaches that (1) develop only during sleep and cause awakening, (2) occur greater than or equal to 10 days per month for greater than or equal to 3 months, (3) last greater than or equal to 15 minutes for up to 4 hours after awakening, and (4) have no associated cranial autonomic symptoms or restlessness.[10] Additionally, the headache should not be accounted for by another ICHD-3 diagnosis.
Other characteristic features of the HH include [11]:
- Timing- Headache usually occurs exclusively with sleep with circadian rhythmicity.[12]
- Age- While it is characterized as a disease of the elderly (>50 years old), it has been reported in the young patient population as well.
- Gender- The disorder appears to affect both genders equally.
- Duration- These headaches are usually short-lasting (30 to 60 min) but can last up to 3 hours.
- Intensity- Usually moderate to severe in intensity, with a small percentage of people reporting mild headaches.
- Character- Most commonly reported character is dull; however, it can be throbbing or pulsating.
- Location- Mostly bilateral and diffuse
- Associated features- These headaches are rarely associated with migrainous (nausea/vomiting or photophobia/phonophobia) or autonomic (lacrimation/conjunctival injection features).
Evaluation
Evaluation of patients with nocturnal headaches must include ruling out conditions like cerebral tumors, giant cell arteritis, obstructive sleep apnea (OSA), and other sleeping disorders.[13]
MRI brain with/without contrast is needed for patients to rule out any structural abnormality like tumors, etc. Overnight polysomnography (sleep) study is necessary to rule out OSA and other sleeping disorders. Once any organic cause of the headache is ruled out, the diagnosis is mostly clinical based on the ICHD-3 diagnostic criteria. MRI brain may also show grey matter volume reduction in the hypothalamus.
Treatment / Management
Treatment and management of headache disorders is a challenging task and requires a thorough evaluation.[14] While there is a lack of good quality clinical data for the management of hypnic headaches, the following medications have shown benefit in the management of hypnic headaches.(B3)
- Lithium - Raskin et al. published the first reports on the effectiveness of lithium for the treatment of HH. Several other studies have been published since then, corroborating their findings. Effective dose- 150 to 600 mg/day in single or divided doses to a serum level of 0.5 to 1.0 mmol/L.
- Indomethacin has shown positive results with the management of HH.[15] It is particularly beneficial in patients with hemicranial hypnic headaches or patients with associated autonomic features. The usual dose for treatment is 25 to 150 mg at bedtime. The physician should be cautious of the side effects while prescribing the medication in the elderly population.[16]
- Caffeine - 40 to 60 mg of caffeine has shown good results in the treatment of HH. It is also very well tolerated in the elderly population and surprisingly does not interfere with sleep. This is often used as a first-line treatment of these headaches.
- Other medications felt ineffective but with conflicting evidence include tricyclic antidepressants, flunarizine, beta-blockers, verapamil, NSAIDs, prednisolone, other anticonvulsants, acetazolamide, melatonin, benzodiazepines, pizotifen, and topiramate.[17]
- There have been case reports suggesting the efficacy of onabotulinum toxin and occipital nerve stimulation.[18][19][20] Physicians must be cautious about the possible complications of such invasive therapies.[21][22] (A1)
Differential Diagnosis
Differential diagnoses of hypnic headache may include other headache disorders that may have a predilection to occur during sleep. These other headache disorders may include migraine, cluster headaches, cervicogenic headache, SUNCT.[23][24][25]
Prognosis
It has been reported that around 17% of patients achieve spontaneous remission over time; however, most patients continue to suffer from it chronically. Another study has reported that 40% of patients achieve freedom from these headaches with treatment. In another published study, 53% of patients enter an episodic course following treatment.[10]
Complications
There are no reported long-term neurologic sequelae to this condition.[26]
Deterrence and Patient Education
As the pathology and exact etiology of these headaches are still unclear, the prevention of these headaches is still not possible. However, prophylactic strategies have demonstrated good outcomes in suppressing the headache attacks.
Enhancing Healthcare Team Outcomes
The diagnosis of hypnic headache is essential as many differential diagnoses are very similar. History taking is the most critical step in the evaluation of these patients and also proper work up to rule out all secondary causes of such headaches like cerebral tumors, etc.
All members of the healthcare team should be familiar with this condition as it is not very common, but it does occur in the real world and must be well managed.
References
Jain S, Malinowski M, Chopra P, Varshney V, Deer TR. Intrathecal drug delivery for pain management: recent advances and future developments. Expert opinion on drug delivery. 2019 Aug:16(8):815-822. doi: 10.1080/17425247.2019.1642870. Epub 2019 Jul 19 [PubMed PMID: 31305165]
Level 3 (low-level) evidenceOlesen J. From ICHD-3 beta to ICHD-3. Cephalalgia : an international journal of headache. 2016 Apr:36(5):401-2. doi: 10.1177/0333102415596446. Epub 2015 Jul 10 [PubMed PMID: 26162775]
Lanteri-Minet M, Donnet A. Hypnic headache. Current pain and headache reports. 2010 Aug:14(4):309-15. doi: 10.1007/s11916-010-0124-8. Epub [PubMed PMID: 20512536]
Level 3 (low-level) evidenceHeadache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia : an international journal of headache. 2004:24 Suppl 1():9-160 [PubMed PMID: 14979299]
Level 1 (high-level) evidenceLiang JF, Wang SJ. Hypnic headache: a review of clinical features, therapeutic options and outcomes. Cephalalgia : an international journal of headache. 2014 Sep:34(10):795-805. doi: 10.1177/0333102414537914. Epub 2014 Jun 18 [PubMed PMID: 24942086]
Holle D, Naegel S, Obermann M. Hypnic headache. Cephalalgia : an international journal of headache. 2013 Dec:33(16):1349-57. doi: 10.1177/0333102413495967. Epub 2013 Jul 5 [PubMed PMID: 23832130]
Donnet A, Lantéri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia : an international journal of headache. 2009 Sep:29(9):928-34. doi: 10.1111/j.1468-2982.2008.01826.x. Epub 2009 Feb 24 [PubMed PMID: 19250282]
Level 3 (low-level) evidenceHolle D, Naegel S, Krebs S, Gaul C, Gizewski E, Diener HC, Katsarava Z, Obermann M. Hypothalamic gray matter volume loss in hypnic headache. Annals of neurology. 2011 Mar:69(3):533-9. doi: 10.1002/ana.22188. Epub 2010 Nov 8 [PubMed PMID: 21446025]
Mathews S, Jain S. Anatomy, Head and Neck, Cricoid Cartilage. StatPearls. 2023 Jan:(): [PubMed PMID: 30969643]
Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology. 2003 Mar 25:60(6):905-9 [PubMed PMID: 12654950]
Goadsby PJ. Unique Migraine Subtypes, Rare Headache Disorders, and Other Disturbances. Continuum (Minneapolis, Minn.). 2015 Aug:21(4 Headache):1032-40. doi: 10.1212/CON.0000000000000195. Epub [PubMed PMID: 26252589]
Dodick DW, Mosek AC, Campbell JK. The hypnic ("alarm clock") headache syndrome. Cephalalgia : an international journal of headache. 1998 Apr:18(3):152-6 [PubMed PMID: 9595209]
Peatfield RC, Mendoza ND. Posterior fossa meningioma presenting as hypnic headache. Headache. 2003 Oct:43(9):1007-8 [PubMed PMID: 14511280]
Level 3 (low-level) evidenceJain S, Silberstein SD. Invited Commentary on Preventive Anti-Migraine Therapy (PAMT). Current treatment options in neurology. 2019 Mar 14:21(4):14. doi: 10.1007/s11940-019-0555-4. Epub 2019 Mar 14 [PubMed PMID: 30868470]
Level 3 (low-level) evidenceIvañez V, Soler R, Barreiro P. Hypnic headache syndrome: a case with good response to indomethacin. Cephalalgia : an international journal of headache. 1998 May:18(4):225-6 [PubMed PMID: 9642499]
Level 3 (low-level) evidenceSeidel S, Zeitlhofer J, Wöber C. First Austrian case of hypnic headache: serial polysomnography and blood pressure monitoring in treatment with indomethacin. Cephalalgia : an international journal of headache. 2008 Oct:28(10):1086-90. doi: 10.1111/j.1468-2982.2008.01611.x. Epub 2008 May 21 [PubMed PMID: 18498399]
Level 3 (low-level) evidenceAl Khalili Y, Sekhon S, Jain S. Carbamazepine Toxicity. StatPearls. 2023 Jan:(): [PubMed PMID: 29939629]
Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia : an international journal of headache. 2007 Sep:27(9):1082-4 [PubMed PMID: 17645763]
Level 3 (low-level) evidenceSon BC, Yang SH, Hong JT, Lee SW. Occipital nerve stimulation for medically refractory hypnic headache. Neuromodulation : journal of the International Neuromodulation Society. 2012 Jul:15(4):381-6. doi: 10.1111/j.1525-1403.2012.00436.x. Epub 2012 Feb 29 [PubMed PMID: 22376140]
Deer TR, Grider JS, Lamer TJ, Pope JE, Falowski S, Hunter CW, Provenzano DA, Slavin KV, Russo M, Carayannopoulos A, Shah JM, Harned ME, Hagedorn JM, Bolash RB, Arle JE, Kapural L, Amirdelfan K, Jain S, Liem L, Carlson JD, Malinowski MN, Bendel M, Yang A, Aiyer R, Valimahomed A, Antony A, Craig J, Fishman MA, Al-Kaisy AA, Christelis N, Rosenquist RW, Levy RM, Mekhail N. A Systematic Literature Review of Spine Neurostimulation Therapies for the Treatment of Pain. Pain medicine (Malden, Mass.). 2020 Nov 7:21(7):1421-1432. doi: 10.1093/pm/pnz353. Epub [PubMed PMID: 32034422]
Level 1 (high-level) evidenceJain S, Fishman MA, Wu C. Significant cephalad lead migration with use of externally powered spinal cord stimulator. BMJ case reports. 2018 Sep 21:2018():. pii: bcr-2018-225813. doi: 10.1136/bcr-2018-225813. Epub 2018 Sep 21 [PubMed PMID: 30244224]
Level 3 (low-level) evidenceDeer TR, Jain S, Hunter C, Chakravarthy K. Neurostimulation for Intractable Chronic Pain. Brain sciences. 2019 Jan 24:9(2):. doi: 10.3390/brainsci9020023. Epub 2019 Jan 24 [PubMed PMID: 30682776]
Jain S, Yuan H, Spare N, Silberstein SD. Erenumab in the treatment of migraine. Pain management. 2018 Nov 1:8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21 [PubMed PMID: 30235976]
Al Khalili Y, Ly N, Murphy PB. Cervicogenic Headache. StatPearls. 2023 Jan:(): [PubMed PMID: 29939639]
Al Khalili Y, Jain S, King KC. Retinal Migraine Headache. StatPearls. 2023 Jan:(): [PubMed PMID: 29939547]
Tariq N, Estemalik E, Vij B, Kriegler JS, Tepper SJ, Stillman MJ. Long-Term Outcomes and Clinical Characteristics of Hypnic Headache Syndrome: 40 Patients Series From a Tertiary Referral Center. Headache. 2016 Apr:56(4):717-24. doi: 10.1111/head.12796. Epub 2016 Mar 26 [PubMed PMID: 27015738]